Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more) Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Virios Therapeutics Inc VIRI

Healthcare Biotechnology
Virios Therapeutics, Inc. is a development-stage biotechnology company. The Company is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel... see more

Recent & Breaking News (NDAQ:VIRI)

Virios Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Thursday, August 12, 2021

Business Wire August 5, 2021

Virios Therapeutics Highlights Clinical Sites Fully Operational in Phase 2b Fibromyalgia Study Featuring FDA "Fast Track" Review Designated Antiviral Therapy, Oral IMC-1

Business Wire July 26, 2021

Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at the International Association for the Study of Pain (IASP) World Congress

Business Wire June 9, 2021

Virios Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating IMC-1 in Patients with Fibromyalgia

Business Wire June 4, 2021

Virios Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update

Business Wire May 13, 2021

Virios Therapeutics to Present at the Benzinga Global Small Cap Conference

Business Wire May 7, 2021

Virios Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on Thursday, May 13, 2021

Business Wire May 6, 2021

Virios Therapeutics, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

Business Wire April 16, 2021

Virios Therapeutics to Present at the Needham Virtual Healthcare Conference

Business Wire April 7, 2021

Virios Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Business Wire March 18, 2021

Virios Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Thursday, March 18, 2021

Business Wire March 11, 2021

Virios Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference in March 2021

Business Wire February 24, 2021

Virios Therapeutics, Inc. Announces Research Collaboration to Explore Role of HSV-1 in Irritable Bowel Syndrome

Business Wire February 1, 2021

Virios Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

Business Wire January 4, 2021

Virios Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-Allotment Option

Business Wire December 21, 2020

Virios Therapeutics Announces Pricing of Initial Public Offering

Business Wire December 16, 2020